IVERIC bio (Nasdaq:ISEE) - Cotización, noticias y análisis

Resumen de acción ISEE

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs.

Acerca de la empresa

ISEE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 68.2% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 59.04%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas han sido diluidos en el último año

Competidores de IVERIC bio, Inc.

Abcam

NasdaqGS:ABCM

US$5.5b

Blueprint Medicines

NasdaqGS:BPMC

US$5.3b

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.9b

Revolution Medicines

NasdaqGS:RVMD

US$6.0b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for IVERIC bio
Historical stock prices
Current Share Price	US$39.95
52 Week High	US$39.99
52 Week Low	US$9.39
Beta	1.1
1 Month Change	4.91%
3 Month Change	39.10%
1 Year Change	236.28%
3 Year Change	791.74%
5 Year Change	1,413.26%
Change since IPO	51.90%

Noticias y actualizaciones recientes

Recent updates

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Sep 06

IVERIC bio Q2 2022 Earnings Preview

Jul 25

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Jul 05

IVERIC bio: A First Take

Jun 23

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

May 20

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Feb 01

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Jul 02

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

Jun 18

IVERIC bio EPS misses by $0.04

May 05

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Mar 12

We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

Nov 27

IVERIC bio EPS misses by $0.05

Nov 02

Rentabilidad de los accionistas

	ISEE	US Biotechs	Mercado US
7D	0.9%	-4.2%	-3.7%
1Y	236.3%	-2.0%	20.5%

Rentabilidad vs. Industria: ISEE superó al sector US Biotechs , que obtuvo un rendimiento del -4.2% el año pasado.

Rentabilidad vs. Mercado: ISEE superó al mercado US, que obtuvo un rendimiento del 14.1% el año pasado.

Volatilidad de los precios

Is ISEE's price volatile compared to industry and market?
ISEE volatility
ISEE Average Weekly Movement	5.4%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: ISEEha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: ISEELa volatilidad semanal ha disminuido de 13% a 5% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2007	163	Glenn Sblendorio	ivericbio.com

Resumen de fundamentos de IVERIC bio, Inc.

¿Cómo se comparan los beneficios e ingresos de IVERIC bio con su capitalización de mercado?
Estadísticas fundamentales de ISEE
Capitalización bursátil	US$5.51b
Beneficios(TTM)	-US$222.90m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-24.7x

Ratio precio-beneficio (PE)

¿Está ISEE sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ISEE
Ingresos	US$0
Coste de los ingresos	US$136.54m
Beneficio bruto	-US$136.54m
Otros gastos	US$86.37m
Beneficios	-US$222.90m

Últimos beneficios comunicados

Mar 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.62
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	20.3%

¿Cómo se ha desempeñado ISEE a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ISEE

Recompensas

Análisis de riesgos

Competidores de IVERIC bio, Inc.

NasdaqGS:ABCM

US$5.5b

NasdaqGS:BPMC

US$5.3b

NasdaqGM:CRSP

US$4.9b

NasdaqGS:RVMD

US$6.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

IVERIC bio, Inc. Files Form 15

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Recent updates

IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

IVERIC bio, Inc. Files Form 15

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Senior VP & COO exercised options and sold US$730k worth of stock

Senior VP & COO notifies of intention to sell stock

Consensus EPS estimates fall by 12%

Forecast to breakeven in 2025

Senior VP exercised options and sold US$2.2m worth of stock

Price target increased by 10% to US$35.09

Forecast to breakeven in 2025

Senior VP notifies of intention to sell stock

Senior VP & COO exercised options and sold US$940k worth of stock

Consensus revenue estimates fall by 13%

Senior VP & COO exercised options and sold US$299k worth of stock

No longer forecast to breakeven

Senior VP & COO exercised options and sold US$314k worth of stock

IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO notifies of intention to sell stock

CEO & Director exercised options and sold US$350k worth of stock

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Forecast to breakeven in 2025

Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO exercised options and sold US$259k worth of stock

Senior VP & COO exercised options to buy US$109k worth of stock.

IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million.

President exercised options to buy US$179k worth of stock.

IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

Price target increased to US$30.17

Senior VP & COO exercised options and sold US$964k worth of stock

IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy

Price target increased to US$26.36

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Senior VP & Chief Commercial Officer exercised options and sold US$138k worth of stock

IVERIC bio Q2 2022 Earnings Preview

IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting

Insider exercised options and sold US$73k worth of stock

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index

IVERIC bio: A First Take

Independent Director recently bought US$241k worth of stock

IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Price target increased to US$24.38

IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

Senior VP exercised options and sold US$261k worth of stock

Senior VP notifies of intention to sell stock

IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

CEO & Director exercised options and sold US$882k worth of stock

CEO & Director exercised options and sold US$122k worth of stock